Welcome to our dedicated page for Diversified Healthcare Tr SEC filings (Ticker: DHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Diversified Healthcare Trust (Nasdaq: DHC), a Maryland real estate investment trust that owns senior living, medical office and life science properties across the United States. Through these filings, investors can review detailed information on DHC’s financial condition, portfolio, capital structure and material events affecting the trust.
Annual reports on Form 10-K and quarterly reports on Form 10-Q contain audited and interim financial statements, segment discussions for the office and senior housing operating portfolios, risk factor disclosures and management’s analysis of results. These documents are central for understanding how DHC’s healthcare real estate assets, including senior living units and medical office and life science properties, contribute to revenue and operating performance.
Current reports on Form 8-K highlight specific events such as the announcement of quarterly financial results, investor presentations, the sale of management agreements for 116 senior living communities to seven different operators, and the issuance and partial redemption of senior secured notes. For example, recent 8-K filings describe DHC’s private offering of 7.250% senior secured notes due 2030, the related redemption of senior secured notes due 2026 and the posting of investor presentations that discuss these transactions.
DHC also has listed debt securities, including 5.625% Senior Notes due 2042 (trading as DHCNI) and 6.25% Senior Notes due 2046 (trading as DHCNL), which are referenced in its filings. Indentures and related agreements filed as exhibits outline covenants that limit additional indebtedness, require certain financial ratios and govern activities of subsidiary guarantors. Investors interested in DHC’s leverage, refinancing activities and covenant structure can analyze these documents for more detail.
On Stock Titan, SEC filings for DHC are updated as they become available from EDGAR. AI-powered tools summarize lengthy reports such as 10-Ks and 10-Qs, highlight key changes from prior periods and explain complex sections in simpler terms. Users can quickly identify items related to senior housing operations, medical office and life science properties, capital recycling, note offerings and redemptions, and other disclosures that shape the risk and return profile of Diversified Healthcare Trust.
Diversified Healthcare Trust reported two key items. First, it incurred an incentive management fee of $17.9 million for the 2025 calendar year under its Business Management Agreement with The RMR Group LLC. This fee is payable in cash by January 30, 2026 and will be recorded as an expense in the company’s financial statements for the year ended December 31, 2025.
Second, on January 9, 2026, the company received a cash dividend of $27.2 million from AlerisLife Inc. in connection with AlerisLife’s sale of all assets and wind-down of its business. Diversified Healthcare Trust expects to receive an additional cash dividend of approximately $3.0 million to $7.0 million upon completion of that wind-down, though the amount or timing may change.
Diversified Healthcare Trust reported that its President, CEO and Director Christopher J. Bilotto purchased 20,000 common shares of beneficial interest on 12/15/2025 at a weighted average price of $4.886 per share, in multiple transactions priced between $4.88 and $4.89.
After these purchases, he beneficially owns 266,284.908 DHC shares directly, which includes 385.018 shares acquired through a dividend reinvestment plan since his last Section 16 filing.
Diversified Healthcare Trust reported Q3 2025 results. Total revenues were $388.706 million, led by resident fees and services of $333.390 million and rental income of $55.316 million. The quarter posted a net loss of $164.040 million (−$0.68 per share), reflecting $93.243 million of impairment charges, interest expense of $48.886 million, and an $11.191 million loss on early debt actions.
Year to date, revenue reached $1.158 billion with a net loss of $264.665 million. The company sold 32 properties for $353.675 million, recording gains of $103.971 million, and classified 50 properties as held for sale. Subsequent to quarter-end, 12 more properties were sold for $42.130 million.
DHC refinanced and reduced near-term debt: it redeemed the entire $380 million 9.75% senior notes due June 2025, issued $375 million of 7.25% senior secured notes due 2030, and partially redeemed senior secured notes due 2026, leaving $334.370 million outstanding. Cash and cash equivalents were $201.371 million. Total assets were $4.684 billion and equity was $1.689 billion as of September 30, 2025.
Diversified Healthcare Trust furnished an update on its business by announcing financial results for the quarter ended September 30, 2025. The company provided a summary press release and a detailed earnings presentation to accompany the results, making them available as Exhibits 99.1 and 99.2. This 8‑K is limited to distributing those materials and does not itself include the underlying figures.
Diversified Healthcare Trust filed a current report noting that it has made a new investor presentation available on its website. On October 8, 2025, the company posted this updated presentation, which is also attached to the report as Exhibit 99.1. The presentation is described as an investor communication and is furnished rather than filed, which typically means it is for informational purposes about the business rather than a formal change to financial statements or contracts.
DIVERSIFIED HEALTHCARE TRUST filed an 8-K reporting the execution of an indenture dated
The report is signed by Matthew C. Brown, Chief Financial Officer and Treasurer, indicating the company completed the documentation for the secured note issuance structure described in the filing.
Matthew C. Brown, the Chief Financial Officer and Treasurer of Diversified Healthcare Trust (ticker DHC), reported a sale of common shares on 09/16/2025. The Form 4 shows 9,711 shares were disposed of at a reported price of $4.37 per share, reducing his beneficial ownership to 113,954 shares. The filing states the disposition code is F(1), and the explanatory note says the transaction represents withholding of shares to satisfy tax withholding obligations upon vesting.
This filing is a routine insider tax-withholding sale rather than an open-market trade, and it was signed by Mr. Brown on 09/18/2025.
Christopher J. Bilotto, who serves as President and CEO and a director of Diversified Healthcare Trust (ticker shown in filing as NASDAQ:DHC), reported a transaction on 09/16/2025 disposing of 17,091 common shares at a price of $4.37 per share. The filing states the shares were withheld to pay a tax liability related to the vesting of previously issued securities. After the withholding, the report shows 245,899.89 common shares beneficially owned by Mr. Bilotto. The Form 4 is signed by the reporting person for this single-person filing.
Adam D. Portnoy, a director of Diversified Healthcare Trust (NASDAQ: DHC), reported a sale of 15,226 common shares on 09/16/2025 at a price of $4.37 per share. The filing lists 415,156.55 shares as his direct beneficial ownership following the transaction and indicates an indirect interest of 23,250,019 shares held by ABP Trust, for which Mr. Portnoy is sole trustee; he disclaims beneficial ownership except to the extent of his pecuniary interest. The filing explains the sale code as F, reflecting withholding of shares to satisfy a tax liability arising from vesting. The Form 4 was signed on 09/18/2025.
Adam D. Portnoy, a director of Diversified Healthcare Trust (NASDAQ:DHC), reported an equity award and resulting holdings. On 09/09/2025 Mr. Portnoy was awarded 81,775 common shares under the issuer's equity compensation plan, a transaction he reported on Form 4 with his signature dated 09/11/2025.
Following the award the filing shows 430,382.55 common shares listed as beneficially owned following the reported transaction and separately discloses 23,250,019 shares held by ABP Trust, of which Mr. Portnoy is sole trustee and which he may be deemed to beneficially own though he disclaims ownership except for his pecuniary interest.